AGM/EGMJul 8, 2026, 04:07 PM
Seres Therapeutics Stockholders Approve 900K Share Increase for Incentive Plan
AI Summary
Seres Therapeutics, Inc. reconvened its 2026 Annual Meeting of Stockholders, where all proposals were approved. Stockholders voted to amend and restate the 2025 Incentive Award Plan, increasing the number of shares available for issuance by 900,000. Additionally, three Class II directors were elected, PricewaterhouseCoopers LLP was ratified as the independent auditor for 2026, and the compensation of named executive officers received advisory approval.
Key Highlights
- Stockholders approved a 900,000 share increase for the 2025 Incentive Award Plan.
- Three Class II directors were elected: Stephen A. Berenson, Claire M. Fraser, and Richard N. Kender.
- PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2026.
- Executive compensation received advisory approval with 3,374,813 votes FOR.
- A proposal to adjourn the meeting, if necessary, was approved but not utilized.
- Approximately 51.75% of outstanding common stock was represented at the meeting.
Price Impact
More from MCRB